Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High Blood Press Cardiovasc PrevJun 29, 2026 (epub)
Luis E Simental-Mendía, Laura Jazel Barragán-Zúñiga, Valeria Reyes-Avitia
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of retatrutide, a triple receptor agonist, on blood pressure and lipid levels in randomized controlled trials. The analysis found that retatrutide significantly reduced systolic blood pressure by 6.79 mmHg and diastolic blood pressure by 2.46 mmHg, along with notable decreases in total cholesterol, LDL-C, and triglycerides.
Key findings
- Retatrutide decreased systolic blood pressure by 6.79 mmHg.
- Diastolic blood pressure was reduced by 2.46 mmHg.
- Total cholesterol levels decreased by 21.88 mg/dL.
- Triglyceride levels were reduced by 40.90 mg/dL.
Why it matters
The findings suggest that retatrutide may offer significant cardiovascular benefits by lowering blood pressure and improving lipid profiles, which are critical factors in managing cardiovascular risk.